KymaThera Raises $80M Series B for Selective PI3Kα Inhibitor

KymaThera announced $80M in Series B financing on October 6, 2026. KymaThera raised an $80 million Series B led by Alta Partners to advance K-1728, an oral PI3Kα inhibitor for cancer and vascular malformations.

Round details

The financing includes backing from Alta Partners, Venrock, Foresite Capital, J. Wood Capital. The company did not publish a valuation with the announcement.

Round: Series B
Capital announced: $80M
Total funding reported: $100M+

How the company plans to use the capital

KymaThera said proceeds will primarily support the advancement of K-1728, and that the financing is expected to fund development through initial clinical proof-of-concept.

Why this matters for GTM teams

The financing follows a 2024 Series A co-led by Foresite Capital and Venrock, both of which participated in the Series B. KymaThera is initially developing K-1728, which is designed to inhibit disease-driving PI3Kα mutations while sparing wild-type PI3Kα, for HR+/HER2- breast cancer and PI3Kα-driven vascular malformations.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: KymaThera Series B announcement.